Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1D1 | P20393 | 1/20 | 0.39 |
| ▸ | RIPK1 | Q13546 | 2/20 | 0.36 |
| ▸ | KCNQ4 | P56696 | 3/20 | 0.35 |
| ▸ | KCNQ5 | Q9NR82 | 3/20 | 0.35 |
| ▸ | KDM1A | O60341 | 2/20 | 0.34 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.34 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.34 |
| ▸ | CTSS | P25774 | 1/20 | 0.34 |
| ▸ | CTSK | P43235 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6872054 | 1.00 | NR1D1 (0.39) | NR1D1RIPK1KCNQ4KCNQ5KDM1A | |
| SCHEMBL6076970 | 0.90 | NR1D1 (0.38) | NR1D1RIPK1KCNQ4KCNQ5KDM1A | |
| SCHEMBL6076961 | 0.90 | NR1D1 (0.38) | NR1D1RIPK1KCNQ4KCNQ5KDM1A | |
| SCHEMBL6871265 | 0.84 | BCL2A1 (0.36) | RIPK1ALDH1A1LMNAMAPTTDP1 | |
| SCHEMBL6871267 | 0.84 | BCL2A1 (0.36) | RIPK1ALDH1A1LMNAMAPTTDP1 | |
| SCHEMBL6881588 | 0.82 | ALDH1A1 (0.40) | RIPK1ALDH1A1LMNAMAPTTDP1 | |
| SCHEMBL6881585 | 0.82 | ALDH1A1 (0.40) | RIPK1ALDH1A1LMNAMAPTTDP1 | |
| SCHEMBL6881196 | 0.82 | RIPK1 (0.39) | RIPK1ALDH1A1LMNAMAPTTDP1 | |
| SCHEMBL6881199 | 0.82 | RIPK1 (0.39) | RIPK1ALDH1A1LMNAMAPTTDP1 | |
| SCHEMBL3681999 | 0.79 | TDP1 (0.39) | RIPK1ALDH1A1LMNAMAPTTDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6777440-B2 | HIV integrase inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2004-08-17 | — | — | US | disclosed |
| US-20030176495-A1 | HIV Integrase inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2003-09-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030176495-A1 | HIV Integrase inhibitors | MAPT, RIF1, HPRT1 | NR1D1 955/4885RIPK1 1438/4885KCNQ4 4624/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.